Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marzia Del Re

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Recenti Progressi in Medicina|December 20, 2018
[Biosimilars in oncology. Focus on SB3 studies.]Marzia Del Re, Lucia Del Mastro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2023
Empower the Potential of Trastuzumab Deruxtecan with Novel CombinationsChristian Rolfo, Marzia Del Re, Alessandro Russo
Cancer|January 18, 2024
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markersChristian Rolfo, Marzia Del Re, Alessandro Russo
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationPaola Bordi, Marzia Del Re, Marcello Tiseo
Translational Lung Cancer Research|December 3, 2015
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerPaola Bordi, Marzia Del Re, Romano Danesi, et al.
Cancer Treatment Reviews|September 16, 2011
Pharmacogenetics of anti-estrogen treatment of breast cancerMarzia Del Re, Angela Michelucci, Paolo Simi, et al.
Annals of Gastroenterology|January 8, 2021
Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center studyStephanie Detailleur, Eva Segelov, Marzia Del Re, et al.
Seminars in Cancer Biology|April 15, 2022
EGFR signaling pathway as therapeutic target in human cancersElena Levantini, Giorgia Maroni, Marzia Del Re, et al.
Journal of Cellular and Molecular Medicine|January 31, 2025
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinibAlessandro Broccoli, Marzia Del Re, Romano Danesi, et al.
European Journal of Pharmacology|November 1, 2024
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatmentsGiorgio Guglielmi, Claudio Zamagni, Marzia Del Re, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Recenti Progressi in Medicina|December 20, 2018
[Biosimilars in oncology. Focus on SB3 studies.]Marzia Del Re, Lucia Del Mastro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2023
Empower the Potential of Trastuzumab Deruxtecan with Novel CombinationsChristian Rolfo, Marzia Del Re, Alessandro Russo
Cancer|January 18, 2024
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markersChristian Rolfo, Marzia Del Re, Alessandro Russo
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationPaola Bordi, Marzia Del Re, Marcello Tiseo
Translational Lung Cancer Research|December 3, 2015
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerPaola Bordi, Marzia Del Re, Romano Danesi, et al.
Cancer Treatment Reviews|September 16, 2011
Pharmacogenetics of anti-estrogen treatment of breast cancerMarzia Del Re, Angela Michelucci, Paolo Simi, et al.
Annals of Gastroenterology|January 8, 2021
Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center studyStephanie Detailleur, Eva Segelov, Marzia Del Re, et al.
Seminars in Cancer Biology|April 15, 2022
EGFR signaling pathway as therapeutic target in human cancersElena Levantini, Giorgia Maroni, Marzia Del Re, et al.
Journal of Cellular and Molecular Medicine|January 31, 2025
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinibAlessandro Broccoli, Marzia Del Re, Romano Danesi, et al.
European Journal of Pharmacology|November 1, 2024
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatmentsGiorgio Guglielmi, Claudio Zamagni, Marzia Del Re, et al.
Pageof 18